中国P站

Schizophrenia; Dopamine hypothesis; Dopamine pathways; Neuropharmacology; Antipsychotics; D2 receptor; Mesolimbic pathway; Mesocortical pathway; Atypical antipsychotics; Dopamine agonists; Dopamine antagonists; Psychosis; Glutamate interaction; Nigrostriatal pathway; Tuberoinfundibular pathway; Extrapyramidal symptoms; Dopamine dysregulation; Pharmacodynamics; Neurobiology of schizophrenia; Receptor binding

Introduction

Schizophrenia is a chronic psychiatric disorder characterized by a constellation of symptoms including hallucinations, delusions, cognitive deficits, and social dysfunction. Among the most enduring theories explaining its pathophysiology is the dopamine hypothesis, which posits that dysregulation of dopamine neurotransmission plays a central role in the onset and progression of the disorder. Neuropharmacological modulation of dopamine pathways, particularly through the use of dopamine receptor antagonists and partial agonists, has remained the cornerstone of schizophrenia treatment for over half a century. This article explores the neuropharmacological mechanisms underpinning dopamine pathway modulation in schizophrenia, with a focus on dopaminergic circuits, drug classes, receptor targeting, and evolving treatment strategies [1,2].

Description

Dopamine (DA) is a critical neurotransmitter involved in reward, motivation, motor control, and neuroendocrine regulation. Its dysregulation has been extensively linked to the neurobiology of schizophrenia. Dopaminergic neurons project through four major brain pathways. Antipsychotic drugs aim to modulate these pathways by interacting with dopamine receptors, primarily the D2 subtype, although newer agents also target D1, D3, and D4 receptors and non-dopaminergic systems [3].

Dopamine hypothesis and receptor pharmacology

The original dopamine hypothesis suggested that schizophrenia resulted from excessive dopaminergic activity, particularly in the mesolimbic system. This was based on findings that drugs increasing dopamine levels (e.g., amphetamines) exacerbate psychosis, while dopamine antagonists ameliorate symptoms. First-generation (typical) antipsychotics, such as haloperidol and chlorpromazine, act primarily as D2 antagonists, reducing mesolimbic dopamine activity and controlling positive symptoms. However, due to non-selective dopamine blockade especially in the nigrostriatal pathway these drugs frequently cause motor side effects (e.g., dystonia, parkinsonism) and tardive dyskinesia with long-term use [4,5].

In contrast, second-generation (atypical) antipsychotics such as clozapine, risperidone, olanzapine, quetiapine, and aripiprazole have dual actions: D2 antagonism or partial agonism and 5-HT2A serotonin receptor antagonism. This broader receptor profile reduces EPS and may provide benefits for negative and cognitive symptoms. Notably, aripiprazole acts as a partial D2 agonist, offering stabilization of dopaminergic tone by acting as an agonist in low-dopamine environments (mesocortical) and as an antagonist in high-dopamine areas (mesolimbic), a concept known as functional selectivity [6,7].

Neuroanatomical basis of dopaminergic dysfunction

Postmortem studies and PET imaging have confirmed elevated presynaptic dopamine synthesis and release in the striatum of patients with schizophrenia, especially in untreated individuals. Conversely, frontal cortical hypodopaminergia has been associated with executive dysfunction and social withdrawal. This imbalance between subcortical hyperdopaminergia and cortical hypodopaminergia underscores the need for region-specific modulation, a goal that current pharmacotherapy approximates only partially [8].

Receptor dynamics and side effects

Antipsychotic efficacy and side-effect profiles depend on binding affinity, receptor occupancy, and kinetic properties. For instance:High D2 occupancy (>80%) is associated with increased risk of EPS. Transient (fast-off) binding to D2 receptors, as seen with clozapine and quetiapine, may mitigate motor side effects while retaining antipsychotic efficacy. Long-acting injectables (LAIs) help maintain therapeutic levels and reduce relapse by improving adherence. Additionally, atypicals may bind to histaminergic (H1), adrenergic (α1), and muscarinic receptors, contributing to side effects such as weight gain, sedation, orthostatic hypotension, and anticholinergic effects [9].

Beyond dopamine: glutamate and gaba interactions

Emerging models of schizophrenia incorporate glutamatergic dysfunction, particularly NMDA receptor hypofunction, which may precede dopaminergic abnormalities. Glutamate modulates dopamine neuron firing through excitatory and inhibitory inputs, and disruptions here could cause upregulated mesolimbic and downregulated mesocortical activity. Moreover, GABAergic interneuron deficits, especially in the prefrontal cortex, are thought to disrupt neural synchrony and impair working memory. These insights suggest that dopaminergic drugs alone may not address the full spectrum of schizophrenia symptoms, particularly cognitive impairments, prompting the exploration of multimodal therapies [10].

Discussion

Evolving Therapies and Research Directions

Clozapine, the most effective antipsychotic for treatment-resistant schizophrenia, acts on multiple receptor systems and has a unique profile in modulating glutamate, serotonin, and GABA in addition to dopamine. However, it carries risks of agranulocytosis, necessitating strict monitoring. Personalized medicine approaches, including genetic profiling (e.g., DRD2 polymorphisms) and neuroimaging biomarkers, are being developed to predict antipsychotic response and tailor treatments more effectively.

Conclusion

The neuropharmacological modulation of dopamine pathways remains a pivotal strategy in the treatment of schizophrenia. Targeting dopamine D2 receptors through antagonism or partial agonism has proven effective in managing positive symptoms, but limitations remain in addressing negative and cognitive symptoms. The complex interplay between dopaminergic circuits and other neurotransmitter systems, particularly glutamate and GABA, indicates the need for broader, more nuanced treatment paradigms. Advancements in pharmacology, receptor biology, and systems neuroscience continue to reshape our understanding of schizophrenia’s neurochemical underpinnings. Novel drugs targeting specific dopamine receptors, in combination with modulators of other neurotransmitter systems, hold promise for improving outcomes and quality of life for individuals with schizophrenia. As research progresses, integrating neuropharmacological knowledge with clinical practice will be essential for optimizing therapeutic strategies in this multifaceted disorder.

References

1. Mahant S, Sharma AK, Gandhi H, Wadhwa R, Dua K et al. (2022) Curr Drug Deliv.

   , ,

2. Cho M, Joo M, Kim K, Wook Y, Lee S (2018) Biochem Biophys Res Commun.

   ,

3. Palugan L, Cerea M, Cirilli M, Moutaharrik S, Maroni A, et al. (2021) Int J Pharm X 3.

   , ,

4. Verma R, Garg S (2001)

5. Keraliya RA, Patel C, Patel P, Keraliya V, Soni TG, et al. (2012) ISRN Pharm 2012.

   , ,

6. Mattos BD, Rojas OJ, Magalh WLE (2017) 142: 4206-4213.

   ,

7. Ding C, Li Z (2017) . Mater Sci Eng C 76: 1440-1453.

   , ,

8. Chen K, Chen X (2010) pp. 1227-1236.

   ,

9. Faheem AM, Abdelkader DH (2020) . Elsevier LTD 1.

10. Pathak C, Vaidya FU, Pandey SM (2019) Elsevier Inc.

    ,